A lively international debate is ongoing around the results of these trials, highlighting the potential limitations of applying combination regimens to all-comers EGFR-mutated NSCLC, in terms of increased toxicities, costs, and logistics, that may lead to restricting the adoption of these combinations. This evidence concerns the gene EGFR and non-small cell lung carcinoma.